

Company Overview

Cellecstar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company's product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently in a clinical study for hematologic malignancies and a pediatric safety study, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

For more information, please visit www.cellecstar.com or join the conversation by liking and following us on the company's social media channels: [Twitter](#), [LinkedIn](#), and [Facebook](#).

Cellecstar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

Mar 2 2021, 8:30 AM EST

Cellecstar to Present at BIO CEO & Investor Digital Conference

Feb 10 2021, 8:30 AM EST

Cellecstar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia

Jan 27 2021, 8:30 AM EST

Stock Overview

Symbol	CLRB	LifeSci Advisors
Exchange	Nasdaq	Monique Kosse
Market Cap	79.08m	Managing Director
Last Price	\$1.74	T: 212-915-3820
52-Week	\$1.01 - \$2.99	monique@lifesciadvisors.com

03/04/2021 04:00 PM EST

Investor Relations

Management Team

James Caruso

President, CEO and Director

Dov Elefant

Vice President and Chief Financial Officer

Dr. John Friend

Chief Medical Officer

Jarrod Longcor

Chief Business Officer

Cellecstar Biosciences, Inc.

100 Campus Drive, Suite 207
Florham Park, NJ 07932

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

